Stem cell therapy in patients with epilepsy: A systematic review

Aligholi, Hadi; Safahani, Maryam; Asadi-Pooya, Ali A.

doi:10.1016/j.clineuro.2020.106416

Cited by 5 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The utility of in vitro stem cell technology by patient-derived iPSCs to high-throughput screening of anti-seizure medications can be applied for personalized epilepsy therapy (Jiao et al, 2013 ; Kaufmann et al, 2015 ; Elitt et al, 2018 ; Lybrand et al, 2020 ). The potential major roles of stem cell therapy in epilepsy are seizure remission, inhibition of the progression of the epileptogenic process, prophylaxis against the development of chronic epilepsy, and improvement of cognitive function (Aligholi et al, 2021 ; Sadanandan et al, 2021 ; Ramos-Fresnedo et al, 2022 ). A phase I clinical trial study showed a favorable seizure reduction, a good safety profile, and improvement of pathological hallmarks in epilepsy patients treated with autologous MSCs (Hlebokazov et al, 2017 ).…”

Section: Therapeutic Applications and Effects Of Stem Cells In Epilepsymentioning

confidence: 99%

Stem Cell Therapy in Treating Epilepsy

Chang

2022

Front. Neurosci.

View full text Add to dashboard Cite

Epilepsy is a common disabling chronic neurological disorder characterized by an enduring propensity for the generation of seizures that result from abnormal hypersynchronous firing of neurons in the brain. Over 20–30% of epilepsy patients fail to achieve seizure control or soon become resistant to currently available therapies. Prolonged seizures or uncontrolled chronic seizures would give rise to neuronal damage or death, astrocyte activation, reactive oxygen species production, and mitochondrial dysfunction. Stem cell therapy is potentially a promising novel therapeutic strategy for epilepsy. The regenerative properties of stem cell-based treatment provide an attractive approach for long-term seizure control, particularly in drug-resistant epilepsy. Embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and adipose-derived regenerative cells (ADRCs) are capable of differentiating into specialized cell types has been applied for epilepsy treatment in preclinical animal research and clinical trials. In this review, we focused on the advances in stem cell therapy for epilepsies. The goals of stem cell transplantation, its mechanisms underlying graft effects, the types of grafts, and their therapeutic effects were discussed. The cell and animal models used for investigating stem cell technology in epilepsy treatment were summarized.

show abstract

Section: Therapeutic Applications and Effects Of Stem Cells In Epilepsymentioning

confidence: 99%

Stem Cell Therapy in Treating Epilepsy

Chang

2022

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Stem cells can be obtained from different regions of the body and are placed in various categories based on several parameters, but they are similar in many aspects ( Table 1 ). Generally, they are divided into two categories, which include embryonic and adult stem cells [ 23 ]. In the following chapters, some of the possible mechanisms of ASMs in combination with mesenchymal stem cells (MSCs) to enhance their therapeutic properties will be investigated.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Epilepsy and Their Interaction with Antiseizure Medications

Tesiye

Gol

Fadardi

et al. 2022

Cells

View full text Add to dashboard Cite

Epilepsy is a life-threatening neurological disease that affects approximately 70 million people worldwide. Although the vast majority of patients may be successfully managed with currently used antiseizure medication (ASM), the search for alternative therapies is still necessary due to pharmacoresistance in about 30% of patients with epilepsy. Here, we review the effects of ASMs on stem cell treatment when they could be, as expected, co-administered. Indeed, it has been reported that ASMs produce significant effects on the differentiation and determination of stem cell fate. In addition, we discuss more recent findings on mesenchymal stem cells (MSCs) in pre-clinical and clinical investigations. In this regard, their ability to differentiate into various cell types, reach damaged tissues and produce and release biologically active molecules with immunomodulatory/anti-inflammatory and regenerative properties make them a high-potential therapeutic tool to address neuroinflammation in different neurological disorders, including epilepsy. Overall, the characteristics of MSCs to be genetically engineered, in order to replace dysfunctional elements with the aim of restoring normal tissue functioning, suggested that these cells could be good candidates for the treatment of epilepsy refractory to ASMs. Further research is required to understand the potential of stem cell treatment in epileptic patients and its interaction with ASMs.

show abstract